Day: November 14, 2024

Earnings Call Webcast to Discuss Third Quarter Financial Results Scheduled to Post to Corporate Website on Monday, November 18, 2024 NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — Reading International, Inc. (NASDAQ: RDI) (“Reading” or our “Company”), an internationally diversified cinema and real estate company with operations and assets in the United States, Australia, and New Zealand, today announced its results for the third quarter ended September 30, 2024. Third Quarter 2024 Summary Results The Company’s third quarter 2024 key financial operating metrics – Total Revenues, Operating Income and Adjusted EBITDA – were all materially stronger than the previous three quarters, indicating that the lingering impacts of the 2023 Hollywood Strikes and the COVID-19 pandemic are coming to an end. During the third quarter 2024, record setting...

PLAINVIEW, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading medtech company with a diversified business portfolio in network and healthcare IT services, professional sales services, and proprietary medical products, today reported its operating results for the three months ended September 30, 2024. “For the third quarter of 2024, the Company’s revenue was $20.8 million, an increase of 7% when compared to the prior year’s third quarter revenue of $19.4 million, mainly due to higher revenue from the network services business in our IT segment.  The Company recorded an operating loss of $1.4 million for the third quarter of 2024 compared to operating income of $907 thousand for the same quarter in 2023, as operating expenses increased including a significant amount in investment banking activities,”...

Net Loss Declines 43% Year-over-Year; Adjusted EBITDA Loss Improves 18% OAKLAND, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Getaround (OTCQB: GETR), the world’s first connected carsharing marketplace, today announced financial results for the third quarter of 2024 ended September 30, 2024. Third Quarter 2024 Highlights Total revenue of $22.4 million versus $23.8 million in the prior-year period Gross Booking Value of $65.1 million compared to $53.0 million as of June 30, 2024 Gross Margin from Service Revenue expanded to 90%, an increase of 300 basis points year-over-year Trip Contribution Margin decreased to 48%, a decrease of 400 basis points year-over-year GAAP net loss of $15.5 million compared to $27.3 million a year ago Adjusted EBITDA loss of $9.3 million versus $11.3 million in 2023 Appointed AJ Lee, Chief Operating...

Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation. Elevai Biosciences Expands Patent Portfolio with EL-22, a Myostatin-Targeting Treatment for Obesity, Addressing Muscle Preservation in Weight Management NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended September 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 $8 Million Public Offering: Elevai raised...

80% YEAR-OVER-YEAR REDUCTION IN LOSSES; COMPANY POISED FOR CONTINUED REVENUE GROWTH AND REACHING SUSTAINED PROFITABILITY IN 2025 WITH REBOUND IN ANIMATION PRODUCTION PIPELINE AND CONTINUING PROFIT IN CHILDREN’S CHANNEL SYSTEM LARGEST REVENUE UNIT, MAINFRAME, SURGING WITH 145 EPISODES IN PRODUCTION FOR NETFLIX, DISNEY, SONY, SPINMASTER, AND MULTIPLE GLOBAL BROADCASTERS HIGHLY ANTICIPATED A.A. MILNE’S WINNIE-THE-POOH, TO RELEASE SNEAK PEEK ANIMATION TRAILER FEATURING TWO NEW FEMALE CHARACTERS BEVERLY HILLS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Kartoon Studios (NYSE American: TOON) today provided a business update for the quarter ended September 30, 2024. Key Highlights Second consecutive quarter of sequential revenue growth Significant cost reductions across all operating units resulting in a 57% decrease in direct operating...

FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company’s already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) — Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. “The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA’s approval to start our pivotal trial of the Acclaim® fully...

— Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors — — Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — –201 Trial Results to be reported in 4Q2024 — BOSTON and ATLANTA, Nov. 14, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent developments. “The financing we concluded in October was a transformational moment for Inhibikase, and positioned us...